• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Beijing Zhongke WengeAI Science And Technology (SEHK:1956) Dropped, So What Is Driving Attention Now?

    Simply Wall St·09/28/2026 09:19:58
    语音播报

    Beijing Zhongke WengeAI Science and Technology (SEHK:1956) has drawn investor attention after a sharp recent pullback, with the share price down 7.5% in the past day and 28.5% over the past month.

    That single-day move sits on top of a broader slide, with the 7-day share price return down 19.2% and the year-to-date share price return down 43.8% at a latest share price of HK$62.75. This signals fading momentum for Beijing Zhongke WengeAI Science and Technology and suggests recent trading is being driven more by changing risk perception than by any fresh re-rating of its long-term potential.

    Scan how Beijing Zhongke WengeAI Science and Technology's sharp pullback compares with other high potential AI plays by checking the hand picked 37 profitable AI stocks that aren't just burning cash in this corner of the market.

    The slide in Beijing Zhongke WengeAI Science and Technology leaves a wide gap between HK$62.75 and where different fair value estimates cluster. Is that gap pointing to mispricing, or is it simply a sign that the share price is catching up with fundamentals?

    Price-to-Sales of 21.9x: Is it justified?

    On simple sales multiples, Beijing Zhongke WengeAI Science and Technology carries a heavy tag, with a P/S ratio of 21.9x while the broader Hong Kong Software industry sits at 1.8x and close peers average 13.6x. That gap is large for a business that is still loss making and trading at HK$62.75, so the valuation hinges on what investors think future revenue and profitability could look like.

    The P/S ratio compares the market value of a company with its annual revenue and is often used for software and AI platforms where earnings are not yet positive. For Beijing Zhongke WengeAI Science and Technology, the current multiple means investors are paying HK$21.90 in market value for every HK$1 of revenue, supported in part by reported top line of HK$459.8m and revenue growth of 27.3% over the past year, despite a net loss of HK$140.4m.

    Set against that, the stock carries clear risk flags. The firm is unprofitable, return on equity is in decline at 11.71% in the red, funding relies entirely on higher risk external borrowing, the share price has been highly volatile over the past three months, and the value score sits at 0. Governance is mixed as well, with an experienced board and management team but only 33% independent directors and CEO compensation rising while the company remains in the red.

    The comparison with peers is stark. A P/S of 21.9x is far above the 1.8x industry average and also above the 13.6x peer group figure, which suggests the market is pricing Beijing Zhongke WengeAI Science and Technology at a significant premium to both its sector and closer comparables.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-Sales of 21.9x (OVERVALUED)

    Still, the Beijing Zhongke WengeAI Science and Technology story could shift quickly if funding costs rise further or if demand in Chinese Mainland slows from current levels.

    Find out about the key risks to this Beijing Zhongke WengeAI Science and Technology narrative.

    Next Steps

    Sentiment around Beijing Zhongke WengeAI Science and Technology is clearly mixed right now, so act while the data is fresh and test the story against your own expectations with the 1 key reward and 1 important warning sign.

    Looking for more investment ideas beyond Beijing Zhongke WengeAI Science and Technology?

    If Beijing Zhongke WengeAI Science and Technology feels too finely priced right now, broaden your watchlist and test fresh ideas before the next move passes you by.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.